Read by QxMD icon Read

stage D3 treatment options

Nebojsa Ignjatovic, Dragan Stojanov, Miodrag Djordjevic, Jelena Ignjatovic, Daniela Benedeto Stojanov, Bobana Milojkovic
Perforation represents a rare and severe complication of gastric cancer (GC) with a large hospital mortality (8-82%). The aim of this study is to evaluate the clinical-pathological features in patients with perforated gastric cancer (PGC) and to advise the surgical treatment options. A total of 11 patients with PGC were retrospectively reviewed among 376 consecutive cases of GC operated. The clinical-pathological features including tumor stage, survival, and the type of treatment were observed. The perforation was more frequent in stage III (8 patients) and in stage IV (3 patients), but none of the cases in stage I and II GC were observed...
July 2, 2016: Bosnian Journal of Basic Medical Sciences
Alice C Shapiro, Susan A Adlis, Kim Robien, Mark N Kirstein, Shuang Liang, Sara A Richter, Rachel E Lerner
The purpose of the study was to evaluate the efficacy and safety of vitamin D3 at 4000 IU/day as a treatment option for aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) when compared with the usual care dose of 600 IU D3. We conducted a single site randomized, double-blind, phase 3 clinical trial in women with AIMSS comparing change in symptoms, reproductive hormones and AI pharmacokinetics. Postmenopausal women ≥18 years with stages I-IIIA breast cancer, taking AI and experiencing AIMSS [breast cancer prevention trial symptom scale-musculoskeletal (BCPT-MS) subscale ≥1...
February 2016: Breast Cancer Research and Treatment
Tatsushi Shingai, Daisuke Sakai, Naotoshi Sugimoto, Tetsuhiro Yoshinami, Toshinari Yagi, Sachiko Yamamoto, Yoji Takeuchi, Koji Higashino, Shingo Noura, Masayuki Ohue, Masahiko Yano
We prospectively evaluated the feasibility of XELOX(oxaliplatin 130 mg/m/(2) on day 1 plus capecitabine 1,000 mg/m(2) twice daily on days 1 to 14 every 3 weeks) for adjuvant treatment in 15 patients with stage III/IV (Japanese classification) colorectal cancer and pathological curability A or B after D2-D3 lymph node dissection. Patients were seen at our institute between September 2009 and January 2012. In the current study, no severe adverse events occurred, including hand-foot syndrome greater than Grade 3, as compared with the MOSAIC, NSABP C-07, and NO16968/XELOXA trials...
February 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Ichiro Tamaki, Kazutaka Obama, Koichi Matsuo, Kazuhiro Kami, Yusuke Uemoto, Teruyuki Sato, Tetsuo Ito, Nobuyuki Tamaki, Keiko Kubota, Hidenobu Inoue, Eiji Yamamoto, Taisuke Morimoto
INTRODUCTION: We report a case of primary adenocarcinoma in the third portion of the duodenum (D3) curatively resected by laparoscopic and endoscopic cooperating surgery (LECS). PRESENTATION OF CASE: A 65-year-old woman had a routine visit to our hospital for a follow-up of rectal cancer resected curatively 2 years ago. A routine screening gastroduodenal endoscopy revealed an elevated lesion of 20mm in diameter in the D3. The preoperative diagnosis was adenoma with high-grade dysplasia; however, suspicion about potential adenocarcinoma was undeniable...
2015: International Journal of Surgery Case Reports
G de Manzoni, G Verlato, M Bencivenga, D Marrelli, A Di Leo, S Giacopuzzi, C Cipollari, F Roviello
BACKGROUND: In gastric cancer the incidence of loco-regional recurrences decreases when lymphadenectomy is expanded from D1 to D2. The present study aimed at evaluating whether the pattern of recurrence in advanced gastric cancer (AGC) is further modified when lymphadenectomy is expanded from D2 to D3. METHODS: 568 patients undergoing curative gastrectomy for AGC (274 D2 and 294 D3) were considered; none of them received preoperative chemotherapy. MantelHaenszel test of homogeneity was used to verify whether the relation between extension of lymphadenectomy and recurrence varied as a function of each risk factor considered...
April 2015: European Journal of Surgical Oncology
Corrado Pedrazzani, Lelde Lauka, Simone Sforza, Andrea Ruzzenente, Filippo Nifosì, GianGaetano Delaini, Alfredo Guglielmi
PURPOSE: In colon cancer (CC), nodal involvement is the main prognostic factor following potentially curative (R0) resection. The purpose of this study was to examine data from the literature to provide an up-to-date analysis of the management of nodal disease with special reference to laparoscopic treatment. METHODS: MEDLINE and EMBASE databases were searched for potentially eligible studies published in English up to July 15, 2014. RESULTS: In CC, nodal involvement is a frequent event and represents the main risk of cancer recurrence...
March 2015: International Journal of Colorectal Disease
James E Frampton
Pramipexole, a non-ergolinic, D3-preferring dopamine agonist (DA), is well established as a treatment option for motor symptoms at all stages of Parkinson's disease (PD). It is administered orally and is available as both a three-times daily immediate-release (IR) formulation and a once-daily extended-release (ER) formulation (Mirapex(®) ER, Mirapexin(®) ER; Pexola(®) ER, Sifrol(®) ER). The two formulations are bioequivalent; the majority (>80 %) of patients can be switched overnight from pramipexole IR to ER without the need for dosage adjustment...
December 2014: Drugs
Yasuhiro Shimada, Tetsuya Hamaguchi, Junki Mizusawa, Norio Saito, Yukihide Kanemitsu, Nobuhiro Takiguchi, Masayuki Ohue, Takeshi Kato, Yasumasa Takii, Toshihiko Sato, Naohiro Tomita, Shigeki Yamaguchi, Makoto Akaike, Hideyuki Mishima, Yoshiro Kubo, Kenichi Nakamura, Haruhiko Fukuda, Yoshihiro Moriya
BACKGROUND: NSABP C-06 demonstrated the non-inferiority of oral adjuvant uracil and tegafur plus leucovorin (UFT/LV) to weekly fluorouracil and folinate (5-FU/LV) with respect to disease-free survival (DFS) for stage II/III colon cancer. This is the first report of JCOG0205, which compared UFT/LV to standard 5-FU/levofolinate (l-LV) for stage III colorectal cancer patients who have undergone Japanese D2/D3 lymph node dissection. METHODS: Patients were randomised to three courses of 5-FU/l-LV (5-FU 500 mg/m(2), l-LV 250 mg/m(2) on days 1, 8, 15, 22, 29, 36 every 8 weeks) or five courses of UFT/LV (UFT 300 mg m(-2)day(-1), LV 75 mg/day on days 1-28 every 5 weeks)...
September 2014: European Journal of Cancer
Vincenza Bagetta, Carmelo Sgobio, Valentina Pendolino, Giulia Del Papa, Alessandro Tozzi, Veronica Ghiglieri, Carmela Giampà, Elisa Zianni, Fabrizio Gardoni, Paolo Calabresi, Barbara Picconi
Dopamine replacement with levodopa (L-DOPA) represents the mainstay of Parkinson’s disease (PD) therapy. Nevertheless, this well established therapeutic intervention loses efficacy with the progression of the disease and patients develop invalidating side effects, known in their complex as L-DOPA-induced dyskinesia (LID). Unfortunately, existing therapies fail to prevent LID and very few drugs are available to lessen its severity, thus representing a major clinical problem inPDtreatment. D2-like receptor (D2R) agonists are a powerful clinical option as an alternative to L-DOPA, especially in the early stages of the disease, being associated to a reduced risk of dyskinesia development...
December 5, 2012: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
Hye Jin Kim, Gyu-Seog Choi, Jun Seok Park, Kyoung Hoon Lim, You Seok Jang, Soo Yeun Park, Soo Han Jun
Situs inversus totalis (SIT) is a rare congenital anomaly characterized by an inversion of the thoracic and abdominal viscera that creates a mirror image. The transposition of the organs imposes special demands on the diagnostic and technical skills of the surgeon, especially when performing laparoscopic surgery. We herein report the case of a 63-year-old man with colon cancer of the hepatic flexure who received a laparoscopic right hemicolectomy. Careful recognition by the surgeon of the mirror image anatomy and skillful use of his left hand resulted in a successful outcome...
November 2011: Surgery Today
Yoshihisa Naito, Yojiro Hashiguchi, Hideki Ueno, Yoshiki Kajiwara, Hideyuki Shimazaki, Hidetaka Mochizuki, Kazuo Hase
A 75-year-old man with advanced undifferentiated rectal cancer, diagnosed by endoscopic biopsy, underwent preoperative short-term chemoradiotherapy (whole pelvis, 4 Gy × 5 day with UFT 400 mg/day × 7 day). Tumor size and lymph node swellings were reduced after radiation therapy. Down-staging was achieved from cT3, cN2, cStage III b to cT3, cN1, cStage III a. A curative low anterior resection with D3 lymphadenectomy including lateral lymph node dissection, was performed 4 weeks after the completion of chemoradiotherapy...
January 2011: Gan to Kagaku Ryoho. Cancer & Chemotherapy
John C Morgan, Kapil D Sethi
Dopaminergic therapies, including levodopa and dopamine agonists, are the mainstays of therapy in Parkinson's disease. With the exception of the injectable short-acting dopamine agonist apomorphine, there is no other widely available non-oral dopaminergic therapy. Rotigotine is a lipid-soluble, non-ergot, D3, D2, D1 dopamine receptor agonist that has demonstrated efficacy as an alternative therapeutic option in both early and advanced Parkinson's disease. More importantly, it is uniquely formulated as a transdermal patch delivery system allowing for continuous, once-daily administration and better patient compliance...
September 2006: Expert Review of Neurotherapeutics
J L Teruel, M T Tenorio, J R Rodríguez, R Marc n, L Orofino, M Rivera, J Ortuño
BACKGROUND: Vitamin D compounds are usually indicated for the treatment of secondary hyperparathyroidism in dialysis patients. The possibility to induce a reversal of hyperparathyroidism with calcium supplementation alone is controversial. The present study was conducted to assess if oral calcium carbonate may constitute a therapeutic option for the control of hyperparathyroidism in patients with high PTH concentrations at the beginning of the treatment with chronic hemodialysis. METHODS: Thirty-one patients with end-stage renal failure with an intact PTH concentration above 250 pg/ml at the beginning of chronic hemodialysis therapy were treated with high doses of calcium carbonate; no patient received either aluminium-containing binders or vitamin D compounds...
1999: American Journal of Nephrology
K L Dechant, K L Goa
A synthetic form of calcitriol (1,25-dihydroxycholecalciferol; 1,25-dihydroxyvitamin D3), the most physiologically active metabolite of vitamin D, has shown efficacy in the treatment of postmenopausal osteoporosis and promise in corticosteroid-induced osteoporosis. Although results of small studies investigating calcitriol in the treatment of postmenopausal osteoporosis have been conflicting, a clinical trial in 622 women with postmenopausal osteoporosis demonstrated that patients with mild to moderate disease who received calcitriol (0...
October 1994: Drugs & Aging
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"